Genesis Bioventures Announces Investor Conference Call and Webcast.LOS ANGELES Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. -- Genesis Bioventures, Inc. (GBI GBI Georgia Bureau of Investigation GBI Green Building Initiative GBI Ground Based Interceptor GBI Grand Bahama Island GBI Green Bank Interferometer GBI Generic Bus Interface GBI Gain By Inventory GBI Garrett Bureau of Investigation ) (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :GBIW) today announced that it has scheduled an investor conference call and webcast to take place on Monday, September 10, 2007 at 4:00 p.m. U.S. ET. Mr. Douglas C. Lane, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will discuss with investors the Company's progress, second quarter performance, and upcoming shareholder meeting.
September 10, 2007 Schedule
3:50 p.m. ET To participate in the conference call,
dial 1-(605)-772-3434 and refer to
Conference Access Code Number 632-461-998
4:00 p.m. ET Conference call begins promptly at 4:00 pm.
September 10, 2007 Simultaneous Webcast
The public may access a live webcast on the conference call by registering for the webcast at https://www.gotomeeting.com/register/264139035 and completing the registration information form. To listen to the audio portion of the webcast participants need to dial in to the conference call number, 1-(605)-772-3434, and refer to Conference Access Code Number 632-461-998. About Genesis Bioventures, Inc. Genesis Bioventures, Inc. is a biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. development corporation focusing on the development and commercialization of its owned and licensed assets for diagnostic and therapeutic product development. The Company holds the exclusive worldwide license to market, sell and distribute PDL's Rapid Assays for prion prion (prī`ŏn), infectious agent thought to cause a group of diseases known as prion diseases or transmissible spongiform encephalopathies. related diseases. Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion